Literature DB >> 19279091

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Kara S Keedy1, Nancie M Archin, Adam T Gates, Amy Espeseth, Daria J Hazuda, David M Margolis.   

Abstract

Silencing of the integrated human immunodeficiency virus type 1 (HIV-1) genome in resting CD4(+) T cells is a significant contributor to the persistence of infection, allowing the virus to evade both immune detection and pharmaceutical attack. Nonselective histone deacetylase (HDAC) inhibitors are capable of inducing expression of quiescent HIV-1 in latently infected cells. However, potent global HDAC inhibition can induce host toxicity. To determine the specific HDACs that regulate HIV-1 transcription, we evaluated HDAC1 to HDAC11 RNA expression and protein expression and compartmentalization in the resting CD4(+) T cells of HIV-1-positive, aviremic patients. HDAC1, -3, and -7 had the highest mRNA expression levels in these cells. Although all HDACs were detected in resting CD4(+) T cells by Western blot analysis, HDAC5, -8, and -11 were primarily sequestered in the cytoplasm. Using chromatin immunoprecipitation assays, we detected HDAC1, -2, and -3 at the HIV-1 promoter in Jurkat J89GFP cells. Targeted inhibition of HDACs by small interfering RNA demonstrated that HDAC2 and HDAC3 contribute to repression of HIV-1 long terminal repeat expression in the HeLa P4/R5 cell line model of latency. Together, these results suggest that HDAC inhibitors specific for a limited number of class I HDACs may offer a targeted approach to the disruption of persistent HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279091      PMCID: PMC2682072          DOI: 10.1128/JVI.02585-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Molecular cloning and characterization of a novel histone deacetylase HDAC10.

Authors:  Amaris R Guardiola; Tso-Pang Yao
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

2.  Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor.

Authors:  Shao-Chung Victor Hsia; Yun-Bo Shi
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

3.  Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.

Authors:  X Zhou; V M Richon; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 4.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

5.  The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Authors:  J J Coull; F Romerio; J M Sun; J L Volker; K M Galvin; J R Davie; Y Shi; U Hansen; D M Margolis
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Authors:  Nancie M Archin; Amy Espeseth; Daniel Parker; Manzoor Cheema; Daria Hazuda; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

8.  Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.

Authors:  Nancy M Archin; Joseph J Eron; Sarah Palmer; Anne Hartmann-Duff; Jeffery A Martinson; Ann Wiegand; Nicholas Bandarenko; John L Schmitz; Ronald J Bosch; Alan L Landay; John M Coffin; David M Margolis
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

9.  DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1.

Authors:  E Verdin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.

Authors:  Loyda Ylisastigui; Nancie M Archin; Ginger Lehrman; Ronald J Bosch; David M Margolis
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

View more
  133 in total

1.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription.

Authors:  Malini Natarajan; Gillian M Schiralli Lester; Chanhyo Lee; Anamika Missra; Gregory A Wasserman; Martin Steffen; David S Gilmour; Andrew J Henderson
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

3.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

4.  Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.

Authors:  Liang Shan; Sifei Xing; Hung-Chih Yang; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Antimicrob Chemother       Date:  2013-09-01       Impact factor: 5.790

Review 5.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

6.  TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

Authors:  So-Yon Lim; Christa E Osuna; Peter T Hraber; Joe Hesselgesser; Jeffrey M Gerold; Tiffany L Barnes; Srisowmya Sanisetty; Michael S Seaman; Mark G Lewis; Romas Geleziunas; Michael D Miller; Tomas Cihlar; William A Lee; Alison L Hill; James B Whitney
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

7.  Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.

Authors:  Li Huang; Wei-Hong Lai; Lei Zhu; Wei Li; Lei Wei; Kuo-Hsiung Lee; Lan Xie; Chin-Ho Chen
Journal:  ACS Med Chem Lett       Date:  2018-02-06       Impact factor: 4.345

8.  Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

Authors:  Guochun Jiang; Erica A Mendes; Philipp Kaiser; Sumathi Sankaran-Walters; Yuyang Tang; Mariana G Weber; Greg P Melcher; George R Thompson; Amilcar Tanuri; Luiz F Pianowski; Joseph K Wong; Satya Dandekar
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

9.  Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Authors:  Koen Bartholomeeusen; Koh Fujinaga; Yanhui Xiang; B Matija Peterlin
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

Review 10.  From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Authors:  Liang Shan; Robert F Siliciano
Journal:  Bioessays       Date:  2013-04-24       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.